Literature DB >> 15238869

[Contrast ultrasound imaging in focal liver lesions: diagnostic value and guidelines].

F Tranquart1, A Bleuzen, J Tchuenbou.   

Abstract

The recent introduction of high quality scanners and contrast agents for ultrasound deeply modifies diagnosis strategy in focal liver lesions by using validated criteria. Non-linear imaging methods using low mechanical index (MI<0.2) and second generation contrast agents allow real-time continuous imaging with concomitant limitation in background tIssue signal and also in agent collapse for a high quality contrast imaging giving dramatic improvement in detection and characterization of lesions. Interpretation is based on the presence of contrast agent within the lesion or not (hyper-, hypo- or isosignal) and the delay after injection (arterial, portal or parenchymal or late phase) as previously used by non-ultrasound methods. This allows an easy differentiation of benign from malignant lesions. Moreover, this allows complete characterization in 85 to 95% of all focal liver lesions and 75% in hepatocellular carcinomas. Those results markedly improve ultrasound accuracy compared to conventional sonography and so put contrast-enhanced sonography among recommended non-invasive imaging methods for focal liver lesions with changes in diagnostic strategy according to the lesion type and actual place of US methods. It is recommended to use contrast ultrasound methods in cancer staging for an optimal detection of liver metastases as well as in characterization of lesions detected during conventional sonography with a consecutive decrease of cost-diagnosis ratio.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238869     DOI: 10.1016/s0221-0363(04)97649-4

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  1 in total

1.  Contrast-enhanced ultrasound of focal nodular hyperplasia: a matter of size.

Authors:  Caroline Bertin; Sophie Egels; Mathilde Wagner; Isabelle Huynh-Charlier; Valérie Vilgrain; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2014-06-25       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.